News | Stent Grafts | May 18, 2016

First Clinical Use of Bioabsorbable Vascular Grafts in Children Shows Promise

Synthetic grafts replaced by body’s own tissue over time offer potential for fewer long-term complications

bioabsorbable vascular graft, children, feasibility study, Bakoulev Center Moscow, AATS 2016 meeting

Image courtesy of Bakoulev Scientific Center for Cardiovascular Surgery

May 18, 2016 — Bioabsorbable heart valves or blood vessels are designed to harness the body’s innate healing process, enabling the natural restoration of complex body parts as the synthetic graft is absorbed. At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, surgeons from the Bakoulev Center for Cardiovascular Surgery, Moscow, reported the results of implantation of bioabsorbable vascular grafts placed into five children born with serious cardiovascular anomalies. According to the investigators, this is the first-ever clinical trial of a bioabsorbable cardiovascular device.

“The positive results of the study provide hope for a new therapeutic approach in cardiovascular valve replacement called Endogenous Tissue Restoration (ETR). This is potentially a revolutionary approach to regenerative medicine in cardiovascular treatment,” said lead investigator Leo Bockeria, M.D.

The procedure was designed to help children born with single-ventricle anomalies, a term used to describe a group of cardiac defects that shares the common feature that only one of two ventricles functions adequately. This can be due to lack of a heart valve, abnormal pumping ability of the heart or other problems. The surgical procedure, known as a Fontan procedure, involves diverting the venous blood from the right atrium to the pulmonary arteries without passing through the area of the right ventricle.

In this prospective, single-center feasibility study, five children aged 4.5 to 12.5 years born with a single-ventricle congenital malformation were implanted with a bioabsorbable graft connecting the inferior vena cava with the right pulmonary artery during an extracardiac Fontan procedure. Patients were followed for 12 months after surgery using echocardiography, computed tomography (CT) scan and magnetic resonance imaging (MRI). No device-related adverse events were reported.

The grafts are composed of supramolecular bioabsorbable polymers, manufactured using a proprietary electrospinning process by European medical device company Xeltis. The grafts have no size limitations, although this study used grafts that were 18 and 20 mm in diameter. Histological studies of the grafts in sheep have shown that graft implantation is followed by initial infiltration of inflammatory cells, which induces physiological healing and tissue formation. This is followed by degradation of the implant scaffold with eventual reduction of the inflammatory response.

The investigators reported that all five patients successfully recovered from the procedure, with significant improvement noted in the patients’ general condition. Imaging studies demonstrate anatomical and functional stability of the grafts.

Although longer follow-up is needed, the investigators said that the procedure has the potential to improve cardiac and vascular surgical procedures by reducing complications resulting from permanently-placed implants. This is especially important for a child who must live with the after-effects of surgery over his lifetime.

The Xeltis bioabsorbable pulmonary heart valve will enter clinical trials in Europe this year. The U.S. Food and Drug Administration (FDA) has recently granted a Humanitarian Use Device (HUD) designation for the device for the the correction or reconstruction of right ventricular outflow tract (RVOT).

For more information: www.aats.org

Related Content

Feature | Cath Lab | September 14, 2021 | By Aaron Detate and Lars Thording
In the electrophysiology (EP) lab, hundreds
An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

An example of the Medis QCA angiography imaging derived fractional flow reserve (FFR) assessment. This technology removes the need for pressure wires and adenosine used in traditional FFR assessments of the coronary arteries.

News | Cath Lab | July 22, 2021
July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of
ast End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System. The 3-in-1 system, which includes a steerable introducer sheath with an ultra-visible positioning balloon and radiofrequency (RF) puncture dilator, aims to provide a predictable and safe solution for electrophysiology (EP) and structural heart interventions requiring left atrial access.
News | Cath Lab | July 14, 2021
July 13, 2021 — East End Medical announced it received U.S.
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...